Silver Book Fact

The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but no optic, disc or visual field deterioration.

Kass M, Heuer D, Higginbotham E, Johnson C, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13. http://archopht.ama-assn.org/cgi/content/abstract/120/6/701

Reference

Title
The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Publication
Archives of Ophthalmology
Publication Date
2002
Authors
Kass M, Heuer D, Higginbotham E, Johnson C, et al.
Volume & Issue
Volume 120, Issue 6
Pages
701-13
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • Laser treatment and vitrectomy reduce the risk of blindness in patients with severe diabetic retinopathy by 90%.  
  • High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • Eye Exams: Trends, 1996-2006 (in relation to screening for diabetic retinopathy)